B.R.A.I.N. Biotechnology Research and Information Network (0RFI) Ratios
B.R.A.I.N. Biotechnology Research and Information Network Ratios
GB:0RFI's free cash flow for Q3 2026 was $-1.23M. For the 2026 fiscal year, GB:0RFI's free cash flow was increased by $1.01M and operating cash flow was $-2.23M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.42 | 1.83 | 1.46 | 1.42 | 3.45 |
| Quick Ratio | 0.91 | 1.45 | 0.90 | 0.97 | 2.83 |
| Cash Ratio | 0.35 | 1.09 | 0.31 | 0.39 | 2.17 |
| Solvency Ratio | -0.10 | -0.08 | -0.08 | -0.05 | -0.03 |
| Operating Cash Flow Ratio | -0.52 | -0.14 | -0.24 | -0.07 | -0.34 |
| Short-Term Operating Cash Flow Coverage | -2.41 | -0.51 | -1.31 | -1.04 | -3.15 |
| Net Current Asset Value | $ -39.54M | $ -29.19M | $ -22.45M | $ -13.36M | $ 3.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.34 | 0.36 | 0.14 | 0.03 |
| Debt-to-Equity Ratio | 13.05 | 2.36 | 1.16 | 0.36 | 0.07 |
| Debt-to-Capital Ratio | 0.93 | 0.70 | 0.54 | 0.27 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.88 | 0.54 | 0.39 | 0.08 | 0.08 |
| Financial Leverage Ratio | 36.03 | 7.03 | 3.26 | 2.63 | 2.00 |
| Debt Service Coverage Ratio | -0.66 | -0.48 | -0.63 | -0.73 | 0.90 |
| Interest Coverage Ratio | -3.86 | -4.57 | -7.13 | -13.16 | -11.84 |
| Debt to Market Cap | 0.35 | 0.47 | 0.18 | 0.04 | 0.02 |
| Interest Debt Per Share | 1.20 | 1.45 | 1.20 | 0.52 | 0.16 |
| Net Debt to EBITDA | -4.28 | -0.63 | -10.10 | -1.77 | -10.87 |
| Profitability Margins | |||||
| Gross Profit Margin | 4.04% | 0.73% | 6.27% | 2.88% | -5.09% |
| EBIT Margin | -18.73% | -16.57% | -11.98% | -11.38% | -5.21% |
| EBITDA Margin | -8.40% | -7.74% | -3.57% | -2.62% | 5.25% |
| Operating Profit Margin | -17.15% | -16.20% | -12.14% | -15.20% | -17.06% |
| Pretax Profit Margin | -24.23% | -20.12% | -13.53% | -12.45% | -11.14% |
| Net Profit Margin | -23.66% | -20.37% | -14.96% | -13.31% | -12.95% |
| Continuous Operations Profit Margin | -23.85% | -20.32% | -14.66% | -12.81% | -12.19% |
| Net Income Per EBT | 97.66% | 101.25% | 110.55% | 106.89% | 116.28% |
| EBT Per EBIT | 141.30% | 124.15% | 111.53% | 81.93% | 65.30% |
| Return on Assets (ROA) | -17.70% | -12.54% | -11.67% | -8.45% | -6.40% |
| Return on Equity (ROE) | -637.81% | -88.19% | -38.03% | -22.23% | -12.82% |
| Return on Capital Employed (ROCE) | -17.46% | -13.89% | -12.56% | -13.29% | -9.86% |
| Return on Invested Capital (ROIC) | -15.93% | -12.23% | -11.55% | -12.69% | -9.53% |
| Return on Tangible Assets | -21.81% | -14.93% | -14.86% | -10.76% | -7.74% |
| Earnings Yield | -24.65% | -24.02% | -8.94% | -6.84% | -2.47% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.51 | 6.90 | 5.79 | 4.36 | 5.52 |
| Payables Turnover | 10.93 | 9.66 | 9.23 | 7.12 | 10.53 |
| Inventory Turnover | 5.33 | 5.79 | 5.32 | 5.00 | 5.75 |
| Fixed Asset Turnover | 1.80 | 1.96 | 1.93 | 1.72 | 1.58 |
| Asset Turnover | 0.75 | 0.62 | 0.78 | 0.63 | 0.49 |
| Working Capital Turnover Ratio | 3.54 | 3.81 | 6.51 | 2.69 | 1.58 |
| Cash Conversion Cycle | 101.28 | 78.21 | 92.22 | 105.43 | 94.88 |
| Days of Sales Outstanding | 66.18 | 52.92 | 63.09 | 83.64 | 66.11 |
| Days of Inventory Outstanding | 68.50 | 63.05 | 68.66 | 73.06 | 63.43 |
| Days of Payables Outstanding | 33.41 | 37.77 | 39.53 | 51.27 | 34.66 |
| Operating Cycle | 134.68 | 115.97 | 131.75 | 156.70 | 129.54 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.42 | -0.16 | -0.19 | -0.07 | -0.20 |
| Free Cash Flow Per Share | -0.49 | -0.24 | -0.31 | -0.35 | -0.26 |
| Dividend Paid and CapEx Coverage Ratio | -6.03 | -2.07 | -1.60 | -0.24 | -3.10 |
| Capital Expenditure Coverage Ratio | -6.03 | -2.07 | -1.60 | -0.24 | -3.10 |
| Operating Cash Flow Coverage Ratio | -0.38 | -0.12 | -0.17 | -0.14 | -1.48 |
| Operating Cash Flow to Sales Ratio | -0.19 | -0.07 | -0.08 | -0.03 | -0.10 |
| Free Cash Flow Yield | -22.60% | -11.47% | -7.40% | -7.85% | -2.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.04 | -4.16 | -11.19 | -14.62 | -40.51 |
| Price-to-Sales (P/S) Ratio | 0.96 | 0.85 | 1.67 | 1.95 | 5.25 |
| Price-to-Book (P/B) Ratio | 25.87 | 3.67 | 4.25 | 3.25 | 5.19 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.42 | -8.72 | -13.51 | -12.73 | -38.98 |
| Price-to-Operating Cash Flow Ratio | -5.16 | -12.93 | -21.96 | -64.88 | -51.57 |
| Price-to-Earnings Growth (PEG) Ratio | -0.69 | -0.12 | -0.42 | -0.73 | 0.78 |
| Enterprise Value Multiple | -15.71 | -11.58 | -56.95 | -76.11 | 89.14 |
| Enterprise Value | 65.47M | 48.97M | 112.60M | 98.64M | 179.52M |
| EV to EBITDA | -15.71 | -11.58 | -56.95 | -76.11 | 89.14 |
| EV to Sales | 1.32 | 0.90 | 2.03 | 1.99 | 4.68 |
| EV to Free Cash Flow | -6.08 | -9.22 | -16.42 | -13.04 | -34.74 |
| EV to Operating Cash Flow | -7.09 | -13.67 | -26.69 | -66.43 | -45.96 |
| Tangible Book Value Per Share | -0.49 | -0.01 | 0.36 | 0.80 | 1.42 |
| Shareholders’ Equity Per Share | 0.08 | 0.58 | 1.00 | 1.36 | 1.94 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | -0.01 | -0.08 | -0.03 | -0.09 |
| Revenue Per Share | 2.27 | 2.50 | 2.53 | 2.27 | 1.92 |
| Net Income Per Share | -0.54 | -0.51 | -0.38 | -0.30 | -0.25 |
| Tax Burden | 0.98 | 1.01 | 1.11 | 1.07 | 1.16 |
| Interest Burden | 1.29 | 1.21 | 1.13 | 1.09 | 2.14 |
| Research & Development to Revenue | 0.08 | 0.00 | 0.09 | 0.10 | 0.14 |
| SG&A to Revenue | 0.14 | 0.09 | 0.05 | 0.04 | 0.04 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Income Quality | 0.79 | 0.32 | 0.51 | 0.23 | 0.83 |
Currency in EUR
